Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.

Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, Buyse M, Sweeney CJ, Regan MM.

JNCI Cancer Spectr. 2019 Feb 6;3(1):pkz002. doi: 10.1093/jncics/pkz002. eCollection 2019 Mar. Review.

2.

Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.

Neven A, Mauer M, Hasan B, Sylvester R, Collette L.

J Biopharm Stat. 2019 Jul 22:1-17. doi: 10.1080/10543406.2019.1641817. [Epub ahead of print]

PMID:
31331234
3.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A.

Eur Urol. 2019 Oct;76(4):437-440. doi: 10.1016/j.eururo.2019.06.006. Epub 2019 Jun 18.

PMID:
31227307
4.

ESMO-MCBS: setting the record straight - Authors' reply.

Lievens Y, Audisio R, Banks I, Collette L, Grau C, Oliver K, Price R, Aggarwal A.

Lancet Oncol. 2019 Apr;20(4):e193. doi: 10.1016/S1470-2045(19)30166-4. No abstract available.

PMID:
30942180
5.

Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.

Altzerinakou MA, Collette L, Paoletti X.

J Natl Cancer Inst. 2019 Mar 5. pii: djz024. doi: 10.1093/jnci/djz024. [Epub ahead of print]

PMID:
30838405
6.

Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective.

Lievens Y, Audisio R, Banks I, Collette L, Grau C, Oliver K, Price R, Aggarwal A.

Lancet Oncol. 2019 Feb;20(2):e112-e123. doi: 10.1016/S1470-2045(18)30917-3. Review.

PMID:
30712798
7.

A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.

Péron J, Marreaud S, Staelens D, Raveloarivahy T, Nzokirantevye A, Flament J, Steuve J, Lia M, Collette L, Schöffski P.

Eur J Cancer. 2019 Mar;109:192-195. doi: 10.1016/j.ejca.2018.12.013. Epub 2019 Jan 14. No abstract available.

PMID:
30655100
8.

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.

Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE.

Scand J Urol. 2018 Oct - Dec;52(5-6):349-357. doi: 10.1080/21681805.2018.1522372. Epub 2019 Jan 9.

PMID:
30624128
9.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J.

JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271.

PMID:
30543350
10.

Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial.

Churilla TM, Chowdhury IH, Handorf E, Collette L, Collette S, Dong Y, Alexander BM, Kocher M, Soffietti R, Claus EB, Weiss SE.

JAMA Oncol. 2019 Feb 1;5(2):243-247. doi: 10.1001/jamaoncol.2018.4610.

PMID:
30419088
11.

Responding to the challenges of international collaborations between the east and the west - report of the first JCOG-EORTC symposium and a perspective from young JCOG and EORTC investigators.

Kataoka K, Kaider-Person O, Kasper B, Starlinger P, Caballero C, Menis J, Hendriks LE, Terada M, Collette L, Nakamura K, Lacombe D, Fukuda H.

Jpn J Clin Oncol. 2019 Jan 1;49(1):96-99. doi: 10.1093/jjco/hyy155.

PMID:
30395275
12.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

13.

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.

Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, Deroose CM, Goffin K, Herrmann K, Hoekstra OS, Kramer G, Lievens Y, Lopci E, Pasquier D, Petersen LJ, Talbot JN, Zacho H, Tombal B, deSouza NM.

Lancet Oncol. 2018 Oct;19(10):e534-e545. doi: 10.1016/S1470-2045(18)30571-0. Epub 2018 Oct 1. Review.

PMID:
30303127
14.

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL).

Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2.

15.

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C.

Clin Trials. 2018 Dec;15(6):624-630. doi: 10.1177/1740774518795637. Epub 2018 Aug 24.

16.

Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042).

Weber DC, Ares C, Villa S, Peerdeman SM, Renard L, Baumert BG, Lucas A, Veninga T, Pica A, Jefferies S, Ricardi U, Miralbell R, Stelmes JJ, Liu Y, Collette L, Collette S.

Radiother Oncol. 2018 Aug;128(2):260-265. doi: 10.1016/j.radonc.2018.06.018. Epub 2018 Jun 28.

PMID:
29960684
17.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2019 Feb 1;30(2):344. doi: 10.1093/annonc/mdx823. No abstract available.

18.

Whole body MRI in spondyloarthritis (SpA): Preliminary results suggest that DWI outperforms STIR for lesion detection.

Lecouvet FE, Vander Maren N, Collette L, Michoux N, Triqueneaux P, Stoenoiu M, Houssiau F, Malghem J, Denis ML, Larbi A, Nzeusseu Toukap A.

Eur Radiol. 2018 Oct;28(10):4163-4173. doi: 10.1007/s00330-018-5377-3. Epub 2018 Apr 17.

PMID:
29666994
19.

Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.

Moschini M, Shariat SF, Rouprêt M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L.

J Urol. 2018 May;199(5):1149-1157. doi: 10.1016/j.juro.2017.11.068. Epub 2017 Nov 20.

PMID:
29158104
20.

Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001.

Churilla TM, Handorf E, Collette S, Collette L, Dong Y, Aizer AA, Kocher M, Soffietti R, Alexander BM, Weiss SE.

Ann Oncol. 2017 Oct 1;28(10):2588-2594. doi: 10.1093/annonc/mdx332.

21.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2017 Dec 1;28(12):3000-3008. doi: 10.1093/annonc/mdx527. Erratum in: Ann Oncol. 2019 Feb 1;30(2):344.

22.

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ; ICECaP Working Group.

J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10.

23.

Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes.

Paoletti X, Drubay D, Collette L.

Clin Cancer Res. 2017 Aug 1;23(15):3977-3979. doi: 10.1158/1078-0432.CCR-17-1306. Epub 2017 Jun 19.

24.

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.

van Leeuwen M, Kieffer JM, Efficace F, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group and Radiation Oncology Group; and the NCRN Testis Clinical Studies Group.

Health Qual Life Outcomes. 2017 May 11;15(1):97. doi: 10.1186/s12955-017-0670-4.

25.

Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership.

Kataoka K, Nakamura K, Caballero C, Evrard S, Negrouk A, Shiozawa M, Collette L, Fukuda H, Lacombe D.

Jpn J Clin Oncol. 2017 Feb 20;47(2):164-169. doi: 10.1093/jjco/hyw159.

PMID:
28173055
26.

From a Comic Opera to Surcare an Open Letter to Whom Clinical Research in Surgery Is a Concern: Announcing the Launch of SURCARE.

Evrard S, Audisio R, Poston G, Caballero C, Kataoka K, Fontein D, Collette L, Nakamura K, Fukuda H, Lacombe D.

Ann Surg. 2016 Dec;264(6):911-912. No abstract available.

PMID:
27828818
27.

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Coens C; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium.

Lancet Oncol. 2016 Nov;17(11):e510-e514. doi: 10.1016/S1470-2045(16)30510-1. Epub 2016 Oct 18. Review.

28.

Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.

Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, Schinagl D, Oei B, Rodenhuis CC, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan DA, Dubois JB, Remouchamps V, Mirimanoff RO, Hart G, Collette S, Collette L, Bartelink H; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups.

JAMA Oncol. 2017 Jan 1;3(1):42-48. doi: 10.1001/jamaoncol.2016.3031.

PMID:
27607734
29.

The European Organization for Research and Treatment for Cancer (EORTC) strategy for quality assurance in surgical clinical research: Assessment of the past and moving towards the future.

Tanis E, Caballero C, Collette L, Verleye L, den Dulk M, Lacombe D, Schuhmacher C, Werutsky G.

Eur J Surg Oncol. 2016 Aug;42(8):1115-22. doi: 10.1016/j.ejso.2016.04.052. Epub 2016 Apr 27. Review.

PMID:
27241924
30.

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L.

J Clin Oncol. 2016 May 20;34(15):1748-56. doi: 10.1200/JCO.2015.64.8055. Epub 2016 Mar 14.

PMID:
26976418
31.

N-of-1 trials in oncology.

Collette L, Tombal B.

Lancet Oncol. 2015 Aug;16(8):885-6. doi: 10.1016/S1470-2045(15)00062-5. No abstract available.

PMID:
26248830
32.

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.

Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J.

Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23.

PMID:
26210894
33.

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A, Maingon P, Valli M, De Winter K, Marnitz S, Barillot I, Scandolaro L, Vonk E, Rodenhuis C, Marsiglia H, Weidner N, van Tienhoven G, Glanzmann C, Kuten A, Arriagada R, Bartelink H, Van den Bogaert W; EORTC Radiation Oncology and Breast Cancer Groups.

N Engl J Med. 2015 Jul 23;373(4):317-27. doi: 10.1056/NEJMoa1415369.

34.

Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer.

Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, Bonnetain F, Bosset JF, Bujko K, Cionini L, Gerard JP, Rödel C, Sainato A, Sauer R, Minsky BD, Collette L, Lambin P.

Radiother Oncol. 2015 Mar;114(3):302-9. doi: 10.1016/j.radonc.2015.02.001. Epub 2015 Feb 21.

PMID:
25716096
35.

Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.

Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB, Liefers GJ, Putter H, van de Velde CJ.

Lancet Oncol. 2015 Feb;16(2):200-7. doi: 10.1016/S1470-2045(14)71199-4. Epub 2015 Jan 12. Review.

PMID:
25589192
36.

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups.

Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25500422
37.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology.

Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.

PMID:
25498218
38.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L.

Eur J Cancer. 2014 Nov;50(17):2983-93. doi: 10.1016/j.ejca.2014.07.011. Epub 2014 Sep 22. Review.

PMID:
25256896
39.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Paoletti X, Le Tourneau C, Verweij J, Siu LL, Seymour L, Postel-Vinay S, Collette L, Rizzo E, Ivy P, Olmos D, Massard C, Lacombe D, Kaye SB, Soria JC.

Eur J Cancer. 2014 Aug;50(12):2050-6. doi: 10.1016/j.ejca.2014.04.030. Epub 2014 Jun 10.

PMID:
24928189
40.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators.

Lancet Oncol. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.

41.

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.

Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC.

Eur J Cancer. 2014 Aug;50(12):2040-9. doi: 10.1016/j.ejca.2014.04.031. Epub 2014 May 28.

PMID:
24880774
42.

Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities.

van Leeuwen M, Efficace F, Fosså SD, Bolla M, De Giorgi U, de Wit R, Holzner B, van de Poll-Franse LV, van Poppel H, White J, Collette L, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group; Radiation Oncology Group.

Eur J Cancer. 2014 Jul;50(11):1957-63. doi: 10.1016/j.ejca.2014.04.018. Epub 2014 May 9.

PMID:
24820932
43.

Adjuvant chemotherapy for rectal cancer--authors' reply.

Bosset JF, Collette L.

Lancet Oncol. 2014 May;15(6):e197-8. doi: 10.1016/S1470-2045(14)70128-7. No abstract available.

PMID:
24807865
44.

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.

Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L; EORTC Radiation Oncology Group.

Lancet Oncol. 2014 Feb;15(2):184-90. doi: 10.1016/S1470-2045(13)70599-0. Epub 2014 Jan 17.

PMID:
24440473
45.

One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?

Pasoglou V, Larbi A, Collette L, Annet L, Jamar F, Machiels JP, Michoux N, Vande Berg BC, Tombal B, Lecouvet FE.

Prostate. 2014 May;74(5):469-77. doi: 10.1002/pros.22764. Epub 2013 Dec 24.

46.

Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.

Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke TM, Knönagel H, Loidl W, Isorna S, Sundaram SK, Collette L; EORTC Genitourinary Cancer Group.

Eur Urol. 2014 Nov;66(5):829-38. doi: 10.1016/j.eururo.2013.07.024. Epub 2013 Jul 24.

PMID:
23932338
47.

Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedure.

Fenton PA, Hurkmans C, Gulyban A, van der Leer J, Matzinger O, Poortmans P, Collette L, Bolla M.

Radiother Oncol. 2013 Jun;107(3):346-51. doi: 10.1016/j.radonc.2013.04.020. Epub 2013 May 23.

PMID:
23707151
48.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group.

Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.

49.

Postoperative radiotherapy for high-risk prostate cancer - Authors' reply.

Bolla M, Collette L.

Lancet. 2013 Mar 30;381(9872):1093. doi: 10.1016/S0140-6736(13)60752-7. No abstract available.

PMID:
23540845
50.

A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results.

Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Mueller RP, Tridello G, Collette L, Bottomley A.

J Clin Oncol. 2013 Jan 1;31(1):65-72. doi: 10.1200/JCO.2011.41.0639. Epub 2012 Dec 3.

Supplemental Content

Loading ...
Support Center